Oragenics, Inc.

Latest News

Oragenics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

Innovative Biopharmaceuticals from Oral Science

At Oragenics, we are focused on developing effective treatments for oral mucositis and becoming a leader in developing novel antibiotics against infectious diseases.

Learn More About Oragenics

Exclusive Collaboration with Precigen

Our exclusive channel collaboration arrangement with Precigen contemplates the use of Precigen’s advanced transgene and cell engineering platforms for the development and production of revolutionary lantibiotics and live biotherapeutic products (LBP).

Learn More About Our Collaborations

Fighting Global Bacterial Antibiotic Resistance

Oragenics, in collaboration with Precigen, is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans.

Learn More About Lantibiotics

Adjunctive Therapy for Oral Mucositis

Oragenics, in collaboration with Precigen, is also in the process of developing live biotherapeutic products (LBP) to treat oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus.

Learn More About LBP

Sign up for email updates

Be the first to receive breaking news

Sign Up

OG716 for C. difficile Infection

OG716 is a molecule derived from our lantibiotic discovery and characterization platform that has shown positive results in nonclinical testing including an animal model for Clostridium difficile infection in enteritis.

More on OG716 »

AG013 for Oral Mucositis

AG013 represents a promising product from a truly innovative platform for the prevention of oral mucositis in cancer patients.

More on AG013 »

Investors Presentation

View our latest Corporate Presentation

View presentation »
Oragenics Pesentation
NYSE American OGEN
Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Last Updated: